Just one month after the European Medicines Agency gave the go-ahead, the European Commission announced on Wednesday 29 July that it had reached an agreement to guarantee access to Remdesivir, marketed under the name Veklury, for treating Covid-19.
“This 63 million euros contract should make it possible to treat around 30,000 patients with severe Covid-19 syndromes”, commented a Commission spokesperson.
Under this agreement, funded by the EU’s Emergency Support Instrument, Member...